“Immuno-Oncology Therapeutics” Featuring Dr. Michael Alonso

On this episode of the Immunology Podcast, Dr. Michael Alonso from Bolt Biotherapeutics talks about using myeloid cells to target tumors.

Dr. Michael Alonso is a Scientific Co-Founder and Vice President of Immunology & Pharmacology at Bolt Biotherapeutics, a biotechnology company developing immunotherapies that activate myeloid cells. He discusses targeting tumors by covering them in “eat me” signals, considerations for moving drugs into the clinic, and building teams in biotech.

We had such an inspiring conversation with Dr. Alonso about science, entrepreneurship, and embracing challenges head on!

Dr. Brenda Raud, host

Find more episodes at immunologypodcast.com or wherever you get your podcasts.

This Episode's Immunology Roundup:

Publish Date: November 02, 2022

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.